Anti-Human ITGB2 Therapeutic Antibody (Hu23F2G (also known as LeukArrest and Rovelizumab))
This antibody immunologically reacts with the common β chain (CD18) of human leukocyte integrins and/or competes with mAb 60.3 for binding to human LFA-1, which is useful for the alleviation of symptoms associated with inflammatory disease states, and more particularly to the inhibition of inflammatory processes associated with the multiple sclerosis disease.
| Supplier | Creative Biolabs |
|---|---|
| Product # | TAB-1582CL |
| Pricing | Inquiry |
| Type | Humanized antibody |
| Applications | IP, FuncS |
| Host | Human |
| Target | CD18 |